InflaRX

News

InflaRx stock halves after it drops lead drug

InflaRx has abandoned its drug development programme, vilobelimab for rare skin disease pyoderma gangrenosum, cratering its share price.

News

InflaRx flatlines after skin disease drug flops in midstage ...

Shares in German biotech InflaRx have plummeted 92% after it reported a comprehensive miss for its lead drug IFX-1 in a debilitating skin disease.

News

CHMP decision levels the playing field for GSK's RSV jab

GSK's RSV vaccine is poised for EU approval in all adults aged 18 and over, bringing it into line with rival shots from Pfizer and Moderna.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Physicians walking and using tablet devices

How to meet your physicians where they are online

A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.

Editor's Picks